Evidence map›Paper›PMID 32098019›Full record

ArticleJournal of clinical medicine2020

Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19).

Tetsuro Kobayashi, Sung-Mok Jung, Natalie M Linton, Ryo Kinoshita, Katsuma Hayashi, Takeshi Miyama, Asami Anzai, Yichi Yang, Baoyin Yuan, Andrei R Akhmetzhanov and 2 more

Registry-linked trialOpen access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04316728 (Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19), which is not on this map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04316728 naunknown statusnot on this map

Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19

TypeinterventionalSponsorCentro Studi Internazionali, ItalyRan2020 to 2020Enrolled200ConditionsCoronavirus InfectionsArmsVivaDiag™ COVID-19 lgM/IgG Rapid Test
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Do Contextual and Demographic Factors Help Malaysian Nurses Prepare in Dealing with the COVID-19 Pandemic?International journal of environmental research and public health · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tetsuro KobayashiGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Sung-Mok JungGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.ORCID 0000-0002-0787-4515
Natalie M LintonGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Ryo KinoshitaGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.ORCID 0000-0002-0116-4598
Katsuma HayashiGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Takeshi MiyamaOsaka Institute of Public Health, Nakamichi 1-3-69, Higashinari, Osaka 537-0025, Japan.
Asami AnzaiGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Yichi YangGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Baoyin YuanGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Andrei R AkhmetzhanovGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.ORCID 0000-0003-3269-7351
Ayako SuzukiGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Hiroshi NishiuraGraduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan.
Hokkaido University · JPOsaka Prefectural Institute of Public Health · JP

Funding

China Scholarship Council NACore Research for Evolutional Science and Technology JPMJCR1413Inamori Foundation NAJapan Agency for Medical Research and Development JP18fk0108050Japan Society for the Promotion of Science H.N.: 17H04701, 17H05808, 18H04895 and 19H01074; R.K.: 18J21587, AS.: 19K24159Ministry of Education, Culture, Sports, Science and Technology NA
6 · The paper itself

Abstract

To understand the severity of infection for a given disease, it is common epidemiological practice to estimate the case fatality risk, defined as the risk of death among cases. However, there are three technical obstacles that should be addressed to appropriately measure this risk. First, division of the cumulative number of deaths by that of cases tends to underestimate the actual risk because deaths that will occur have not yet observed, and so the delay in time from illness onset to death must be addressed. Second, the observed dataset of reported cases represents only a proportion of all infected individuals and there can be a substantial number of asymptomatic and mildly infected individuals who are never diagnosed. Third, ascertainment bias and risk of death among all those infected would be smaller when estimated using shorter virus detection windows and less sensitive diagnostic laboratory tests. In the ongoing COVID-19 epidemic, health authorities must cope with the uncertainty in the risk of death from COVID-19, and high-risk individuals should be identified using approaches that can address the abovementioned three problems. Although COVID-19 involves mostly mild infections among the majority of the general population, the risk of death among young adults is higher than that of seasonal influenza, and elderly with underlying comorbidities require additional care.

Indexed as

emerging infectious diseasesfatalitystatistical estimationvirulencevirus

Identifiers

PMID32098019
PMCPMC7073841
OpenAlexW3008507814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.